On February 6, the European Parliament voted on a draft report about a proposal relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of public health insurance systems.
The report was adopted in the parliamentarian plenary with 559 votes in favor, 54 against and 72 abstentions.
As EPHA published this week, “Members of the European Parliament (MEPs) have been demanding more transparency on medicine pricing.” MEPs asked for a 60-day time limit to decide on the pricing and reimbursement of generic medicines. Concerning new medicines, these products will have to respect the current timeline of 180 days.
A list of experts and members, as well as their declarations of interest, should be released to ensure transparency during the whole process. The European Parliament also recommended the publication, at least once a year, of a report on medicinal products covered by public health insurance systems, together with their prices.
Following the adoption of the report, MEP Antonyia Parvanova (Bulgaria; Alliance of Liberals and Democrats for Europe) will negotiate an agreement with the Council of Ministers.
For further information:
EPHA related articles: